Krebs Biochemicals Q1 FY27 Unaudited Results: Net Loss Widens to ₹248.48 Lacs
Krebs Biochemicals reported Q1 FY27 un-audited results with revenue from operations at ₹698.35 lacs. The company posted a net loss of ₹248.48 lacs for the quarter ended June 30, 2026, compared to a loss of ₹532.43 lacs in Q1 FY26. The Board approved the results on August 6, 2026. The amalgamation with IPCA Laboratories is proceeding.
The net loss and ongoing operational issues (Vizag unit closure) have a moderate impact on the company's financial health and operations. The pending amalgamation could significantly alter the future impact.
The company reported a widening net loss in the quarter despite an increase in revenue, indicating financial challenges.
Krebs Biochemicals and Industries Limited announced its un-audited financial results for the first quarter ended June 30, 2026. The company's Board of Directors approved and took on record the financial results and the Limited Review Report by the Auditors during a meeting held on August 6, 2026.
The meeting commenced at 11:30 am and concluded at 01:30 p.m. The results indicate a revenue from operations of ₹698.35 lacs for the quarter, an increase from ₹548.09 lacs in the same quarter of the previous year. However, total expenses rose significantly to ₹962.48 lacs from ₹1,081.69 lacs in the prior year's corresponding quarter, although lower than ₹1,115.23 lacs in the previous quarter. The company reported a loss before exceptional items and tax of ₹248.48 lacs for the quarter, compared to a loss of ₹532.43 lacs in the first quarter of the previous fiscal year. The total comprehensive income for the period was also a loss of ₹248.48 lacs.
Key notes from the announcement include that the company's Vizag manufacturing unit remains closed due to an order from the Andhra Pradesh Pollution Control Board, and the company is actively engaging with the board for revocation. Additionally, the Board of Directors had previously approved the amalgamation of Krebs Biochemicals & Industries Limited with IPCA Laboratories Limited on June 26, 2026, with an appointed date of April 1, 2026, subject to necessary approvals. The company operates in a single segment and has no subsidiaries, associates, or joint ventures as of June 30, 2026. The statutory auditors have issued an unmodified report on the financial results.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.